HomeBIOVF • OTCMKTS
add
Swedish Orphan Biovitrum AB (publ)
Previous close
$30.50
Year range
$24.08 - $32.25
Market cap
106.73B SEK
Avg Volume
170.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 6.46B | 3.34% |
Operating expense | 3.52B | 7.71% |
Net income | 875.00M | 9.38% |
Net profit margin | 13.53 | 5.79% |
Earnings per share | 2.72 | 1.87% |
EBITDA | 2.39B | 0.42% |
Effective tax rate | 20.16% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 997.00M | 89.18% |
Total assets | 70.12B | -5.90% |
Total liabilities | 31.08B | -19.51% |
Total equity | 39.04B | — |
Shares outstanding | 343.46M | — |
Price to book | 0.27 | — |
Return on assets | 4.98% | — |
Return on capital | 6.58% | — |
Cash Flow
Net change in cash
| (SEK) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 875.00M | 9.38% |
Cash from operations | 2.30B | 1.73% |
Cash from investing | -94.00M | 87.38% |
Cash from financing | -2.29B | -22.95% |
Net change in cash | -143.00M | 62.07% |
Free cash flow | 2.38B | 2,297.81% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,895
